CN110384234A - A kind of raising spacefarer body function compound formulation - Google Patents
A kind of raising spacefarer body function compound formulation Download PDFInfo
- Publication number
- CN110384234A CN110384234A CN201910006301.8A CN201910006301A CN110384234A CN 110384234 A CN110384234 A CN 110384234A CN 201910006301 A CN201910006301 A CN 201910006301A CN 110384234 A CN110384234 A CN 110384234A
- Authority
- CN
- China
- Prior art keywords
- spacefarer
- powder
- phosphatidylserine
- raising
- body function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 title claims abstract description 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 47
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 38
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 35
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000000843 powder Substances 0.000 claims abstract description 32
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 24
- 244000126014 Valeriana officinalis Species 0.000 claims abstract description 23
- 235000013832 Valeriana officinalis Nutrition 0.000 claims abstract description 23
- 235000016788 valerian Nutrition 0.000 claims abstract description 23
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 20
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 17
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 17
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 16
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 16
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 235000019871 vegetable fat Nutrition 0.000 claims abstract description 15
- 241000229143 Hippophae Species 0.000 claims description 20
- 229920001503 Glucan Polymers 0.000 claims description 15
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 229940042126 oral powder Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 230000001976 improved effect Effects 0.000 abstract description 12
- 229920002498 Beta-glucan Polymers 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000003712 anti-aging effect Effects 0.000 abstract description 3
- 239000006210 lotion Substances 0.000 abstract description 2
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 description 25
- 230000006870 function Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 241000700159 Rattus Species 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 11
- 241000169546 Lycium ruthenicum Species 0.000 description 11
- 229940067606 lecithin Drugs 0.000 description 11
- 239000000787 lecithin Substances 0.000 description 11
- 235000010445 lecithin Nutrition 0.000 description 11
- 230000015654 memory Effects 0.000 description 11
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 210000000170 cell membrane Anatomy 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229930014669 anthocyanidin Natural products 0.000 description 5
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 5
- 235000008758 anthocyanidins Nutrition 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229910052759 nickel Inorganic materials 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004958 brain cell Anatomy 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 239000010941 cobalt Substances 0.000 description 4
- 229910017052 cobalt Inorganic materials 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000005915 GABA Receptors Human genes 0.000 description 3
- 108010005551 GABA Receptors Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000002758 humerus Anatomy 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 210000002303 tibia Anatomy 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010062745 Chloride Channels Proteins 0.000 description 2
- 102000011045 Chloride Channels Human genes 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000007177 brain activity Effects 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 231100000567 intoxicating Toxicity 0.000 description 2
- 230000002673 intoxicating effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 125000001095 phosphatidyl group Chemical group 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- FEBNTWHYQKGEIQ-SUKRRCERSA-N valerenic acid Chemical compound C[C@@H]1CC[C@@H](\C=C(/C)C(O)=O)C2=C(C)CC[C@H]12 FEBNTWHYQKGEIQ-SUKRRCERSA-N 0.000 description 2
- FUHPCDQQVWLRRY-UHFFFAOYSA-N valerenic acid Natural products CC1CCC(C=C(/C)C(=O)O)C2C1CC=C2C FUHPCDQQVWLRRY-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 244000134336 Malus baccata Species 0.000 description 1
- 235000005079 Malus baccata Nutrition 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- PASCVNXEVINGGG-UHFFFAOYSA-N Mollic acid Natural products CC(CCC=C(C)C)C1CCC2(C)C3CCC4C(C)(C(O)CC(O)C45CC35CCC12C)C(=O)O PASCVNXEVINGGG-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000010220 ion permeability Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000012241 membrane hyperpolarization Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a kind of raising spacefarer body function compound formulation, said preparation is made of following raw materials according: soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, oat-beta glucan, vegetable fat powder, maltodextrin.Spacefarer's body function can be improved in preparation provided by the invention, and spacefarer is made more smoothly to complete aerial mission.In addition, this preparation also has anti-aging, the effect of beautifying face and moistering lotion.
Description
Technical field
The present invention relates to a kind of pharmaceutical formulation, in particular to a series of changes occur for body during a kind of flight for spacefarer
The pharmaceutical formulation of change and process flow.
Background technique
Numerous studies report that under weightlessness, a series of adaptability will occur for heart, blood vessel and its neural modulation system
Variation, and then cause cardiovascular function low.Under state of weightlessness, body body fluid is shifted to head, increases thoracic cavity and head blood volume
Add, urine volume increases, hypovolemia;Increased heart rate simultaneously, heart are often won output quantity and are reduced, especially the flight of experience long term space
Afterwards, cardiac ejection fraction and ejection time percentage reduce, and left room is shunk last volume and increased, decreased cardiac function.Weightlessness may be used also
To cause animal cardiovascalar system to will appear organic variation: such as myocardial atrophy, locular wall is thinning, aortic smooth amyotrophia and pipe
Chamber, which becomes larger, waits pathological changes, and long-term space travel, can lead to lower limb antigravity muscle (such as thigh quadriceps muscle of thigh in astronaut's process
Deng) there is apparent atrophic variation;Weightlessness can cause bone amount quickly to be lost.Studies have reported that spacefarer's ridge after space flight
The bone mineral density (BMD) of vertebra, femur and pelvis monthly reduces by 1.0 %-1.6 %.Under the space environment in 4- June, ridge
Column entirety bone bulk-forming (v) BMD is reduced with the speed of monthly 0.9 %, and cancellous bone vBMD monthly reduces by 0.9 %, and hip
Monthly Loss Rate is respectively 1.2 % -1.5 %, 0.4 %-0.5 % and 2.2 to the vBMD of whole, cortex bone and cancellous bone
%-2.7 %;Weightlessness can also lead to the ill symptoms such as astronaut's endocrine disorder, immunologic hypofunction, gastrointestinal disorder.For space flight
Member can be healthy and smoothly completes aerial mission, it is necessary to research and develop a kind of pharmaceutical formulation that can be improved spacefarer's body function.
Summary of the invention
The purpose of the present invention is improving spacefarer's body function in all its bearings, aerial mission is smoothly completed.
In order to complete the purpose of the present invention, a kind of raising spacefarer body function compound formulation is made of following raw material: big
Fabaceous Lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, avenabeta glucosan plant rouge
End, maltodextrin.The component raw material weight ratio of said preparation is as follows:
Soybean lecithin 20%-30%
Phosphatidylserine 15%-18%
4-Aminobutanoicacid 15%-18%
Valerian root P.E 10%-15%
Black fruit fructus lycii 10%-12%
Seabuckthorn fruit powder 8%-10%
Avenabeta glucosan 5%-10%
Vegetable fat powder 2%-5%
Maltodextrin 1%-2%
Specific production technology is as follows:
By soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, oat β-Portugal gathers
Sugar, vegetable fat powder, maltodextrin are pulverized and mixed uniformly, cross 80 meshes, control environment temperature and humidity, and certain specification is dressed up in drying
Pulvis.
A kind of raising spacefarer body function compound formulation provided by the invention, the effect of main component soybean lecithin is:
Soybean lecithin is the essence substance extracted from soybean.It is also one of the lipid component that human body needs.
1, it delays senescence
The cell for constituting human body has 60,000,000 hundred million.1 second will be 500,000 dead, while regenerating 500,000.With the increasing at age
Long, the quantity of cell death will be more and more, and regenerated cell is fewer and fewer.When cell death number is greater than regeneration number,
People begins to aging.The metabolic processes of cell are regulated and controled by cell membrane, the health degree of cell membrane, direct relation
To the self-repairing capability of cell, information transfer capacity, the ability for resisting external aggression, cell activity and power of regeneration etc..Carefully
After birth is mainly to be made of lecithin, supplements lecithin to human body, it is meant that can repair the cell membrane being damaged, improve
Cell membrane function makes cell membrane softening and rejuvenation, increases cell activity.Pass through the intake to lecithin, so that it may improve people
Metabolic capability, the power of regeneration of self-healing ability and antibody tissue of body, enhance the vitality of human body, fundamentally delaying human body
Aging.
2, blood vessel scavenger, prevention cardiovascular and cerebrovascular disease
Lecithin can emulsify, cut grease, and can make by the cholesterol being attached on vascular wall and fat emulsification at particulate
Be dissolved in blood and transport liver back and be metabolized.Play the role of softening blood vessel, improve serum lipids, removes peroxide, make
Blood Cholesterol and fat content reduce, to reduce blood viscosity, promote blood circulation, reduce fat in the blood vessels
Residence time.In turn, the blood for making full of nutrition, oxygen-containing abundance, flows to the organs such as brain, heart unblockedly.Japan's celebrating
It answers University Medical College food nutrition system once to do clinical trial, and concludes that by taking lecithin, can be effectively reduced
High blood lipid and cholesterol, and then the diseases such as prevention and treatment of coronary heart disease, hypertension, myocardial infarction, cerebral thrombosis, cerebral hemorrhage, artery sclerosis.
3, brain tonic and intelligence development, prevention senile dementia
Lecithin can provide sufficient nutriment for brain nervous cell, accelerate the information transmission speed between cranial nerve, thus
Brain activity is improved, brain fag is eliminated, keeps human thinking quick, improves study and work efficiency.Lecithin is impaired in reparation
While hurting brain cell, get through obstacle between brain and blood circulation, the normal function of cranial nerve cell can be maintained, and is enhanced big
Cerebral nervous system function, and then reach the effect of preventing senile dementia.
4, the patron saint of liver
Heavy drinking or overnutrition can aggravate the burden of liver cell, reduce the ability of liver synthetic phospholipid.When phosphorus in human body
Rouge lack of choline will lead to a large amount of accumulations of the fat in liver, form fatty liver, be destroyed liver cell, liver function subtracts
It moves back, causes cirrhosis even liver cancer.Science proves: liver cell metabolism can be enhanced by mending food lecithin, promoted fat acid decomposition, protected
Protect liver is dirty, the generation of the illnesss such as prevention fatty liver.
5, the nutriment of diabetes patient
Lecithin can enhance pancreatic functions, repair Stem Cells, and the insulin for keeping its secretion sufficient reduces blood glucose, effectively will
Glucose transport in blood is into cell, to mitigate diabetic condition.
6, the main component for constituting biomembrane, is the indispensable base substance of human body
Lecithin can promote spirit to pass to, and improve brain activity, and due to can effectively prevent gallbladder with good emulsibility
Sterol precipitates in vascular wall and removes partly precipitated object, so that playing reduces serum cholesterol, reduce blood viscosity, promote blood
Circulation, prevents the effect of cardiovascular disease.Therefore the product for often eating the soft phosphatide containing soybean, can effectively adjust blood lipid and gallbladder
Sterol improves cerebral function, improves memory, prevents and treats fatty liver etc..
The effect of main component phosphatidylserine:
Phosphatidylserine (PS), one big emerging " intelligent nutrition element " being known as after choline and " docosapentaenoic acid " DHA.
Expert thinks that this natural materials can help cell wall to keep flexibility, and can enhance the nerve of transmission brain signal
The efficiency of mediator helps brain high-efficiency operation, excites the state of activation of brain.Specifically, phosphatidylserine has following function
Energy.
1, cerebral function is improved, is focused on, memory is improved
America and Europe emerges largely that (meta-analysis refers to the multiple independences done to some problem to the meta-analysis of phosphatidylserine
Result of study carries out quantitatively or qualitatively integrating for system), main purpose is by the more objective ground heddle of previous result of study
Conjunction reflects.Someone analyzes 9 double blinds, placebo, the clinical test that totally 1224 patients participate in, the results show that
After supplementing phosphatidylserine, the parameter about cognition and memory significantly improves.Unquestionably, phosphatidylserine is supplemented
Long-term memory, long-term cognition and free talk and logicality speech ability can be improved.With advancing age, phosphatidyl silk
Propylhomoserin and other important intracerebral chemical substances can gradually decrease, and weaken so as to cause memory, cognitive power.Supplement phosphatidyl silk
Propylhomoserin can increase brain bur number, the mobility of brain cell membrane and promote glucose metabolism in brain cell, to make brain cell more
It is active, promote attention to concentrate, stepping up vigilance property and memory.Italy, the Scandinavian Peninsula and European other countries
Phosphatidylserine replenishers are widely applied all to treat the cognitive disorder disease of aging initiation and old memory loss.
2, student performance is improved
Once someone specially tested the effect that phosphatidylserine alleviates stress, and test uses double blind, placebo,
Continuous 30 days, 300 milligrams of phosphatidylserines of Health College Students are given once daily.University student must complete to have within given time
The mathematics test of certain difficulty, and record them and face the reaction of pressure.As a result, it has been found that the student using phosphatidylserine exists
Reagency, confidence and performance aspect are better than control group, their achievements in examination are also more preferable.One research is directed to 120
The research of Chongqing SiChuan middle school Senior student also found, take the student for strengthening phosphatidylserine, after 40 days,
The memory of language and non-language is all significantly increased.
3, it relieves stress, promotes recovery, the balance mood of brain fag
Multiple studies have shown that the level of stress hormone excessive in phosphatidylserine can significantly reduce work strain person's body, subtracts
Light pressure alleviates brain fatigue;Phosphatidylserine, which may also act to big intracerebral, influences the neurotransmitter levels of mood, can promote
Into attention concentration, stepping up vigilance property and memory, improper release mood (such as depressed, dejected) is helped.
4, it helps to repair brain damage
Phosphatidylserine is one of main component of brain neuroblastoma, can nutrition and activation brain in various enzymes activity, can delay
The reduction process of neurotransmitter helps to repair, updates brain damaged cell and remove harmful substance.It can make the elderly's
Memory is restored to the level before 14 years, and after studies have shown that edible phospholipid acyl serine 12 weeks, 66 years old people has 52 years old people
Memory.
In addition to this, phosphatidylserine and DHA can mutually promote absorption, play a protective role to 2 A cells of nerve
.Phosphatidylserine abundant can increase the mobility of cell membrane, promote the development of intelligence.Phosphatidylserine and DHA mono-
It rises and can protect central nervous system, promote fetal intelligence development.
Studies have shown why phosphatidylserine can enhance the intelligence of people, main reason is that it can wear rapidly
Blood-brain barrier is crossed, into brain.Play the role of cerebral capillary smooth muscle cell of releiving in brain, increases brain blood supply.
So there is many products in terms of cerebral apoplexy all using PS as raw material in recent years.
The effect of main component 4-Aminobutanoicacid:
4-Aminobutanoicacid is inhibitory neurotransmitter critically important in central nervous system, it is a kind of naturally occurring non-protein
Amino acid is formed, there is extremely important physiological function, it can promote the reactivity of brain, brain tonic and intelligence development, and anti-epileptic promotes to sleep
It sleeps, beauty moisturizing delays brain aging function, can supplement human body inhibitory neurotransmitter, has good blood pressure reduction effect.Promote
Kidney Fitness improvement and protective effect.Inhibit fatty liver and obesity, activates liver function.The micro 4-Aminobutanoicacid of daily iron supplement has
Conducive to the alleviation of heart and brain blood pressure, and the balance of amino acid metabolism in human body can be promoted, adjust immune function.
4-Aminobutanoicacid belongs to strong neural inhibitory aminoacid, has calmness, hypnosis, anticonvulsion, blood pressure lowering physiological action.
It is inhibitory neurotransmitter (Inhibitory Neurotransmitter), can inhibit the activity of animal, reduce energy
Consumption.Aminobutyric acid acts on the GABA receptor in zooblast, and GABA receptor is a chloride channel, the inhibition of GABA
Or excitability is to rely on the chlorine ion concentration inside and outside cell membrane, after GABA receptor is activated, causes chloride channel open,
Cell membrane be can increase to chloride ion permeability, chloride ion is flowed into nerve cell, cause cell membrane hyperpolarization, inhibit nerve thin
Cell element excitement, to reduce the amount of exercise of animal.
It is the unintentional motion by reducing animal, to reduce energy consumption, to reach somatotrophic purpose.γ-
Aminobutyric acid can promote the secretion of animal gastric juice and growth hormone, to improve the speed of growth and feed intake;The excited animal of energy
Feeding maincenter, to increase feed intake.
The effect of main component Valerian root P.E:
1. angst resistance effect: the experiment proves that both the main component valerenic acid of Valerian root P.E and valerienol can be reinforced
The reaction of γ-aminobutyric acid (GABA) receptor.Experiment discovery administration group (valerenic acid and valerienol) rat blood serum cortisone
Level is significantly reduced, and all shows that valerian has apparent angst resistance effect.
2. antidepressant effect: valerian has the function of depressive state behavior different degrees of.Valerian is green non-poisonous secondary work
Calm, hypnosis and anticonvulsion is at home and abroad widely used in sleeping substance.Can allow in human feelings thread becomes mild.
3. promoting blood circulation and blood tonification effect: valerian is sweet in flavor, and master enters the heart channel of Hang-Shaoyin, has effects that mental-tranquilization.Had no peace of mind with controlling, usually
With semen ziziphi spinosae, etc. sleepings plant with use;If the insufficiency of heart and spleen, can the invigorating QI and bloods such as compatibility Radix Angelicae Sinensis, Radix Astragali, Radix Codonopsis, arillus longan medicine.
4. research discovery valerian has treatment blood stasis, traumatic injury.Effect has alleviation epigastric pain in fact, and wound goes out
Blood and the effects of grinding external application.
The effect of main component black fruit fructus lycii:
1, lycium ruthenicum can with blood-enriching tranquillizing, improve sleep, and can prevent wrinkle of skin ahead of time generate, be current nature most
Effective antioxidant.It can not only prevent generating ahead of time for wrinkle of skin, more can supplement the nutrients and eliminate and is harmful in vivo
Free radical.
2, the anthocyanidin in lycium ruthenicum is natural sunlight overcover, can prevent injury of the ultraviolet light to skin.
3, lycium ruthenicum has the function of apparent reducing blood lipid, adjusts lipid metabolism, has to prevention cardiovascular disease and actively makees
With.Lycium ruthenicum have it is hypoglycemic, the activity of superoxide dismutase in damaged islet cells can be remarkably reinforced in lycium ruthenicum polysaccharide, mention
The oxidation resistance of high islet cells mitigates damage of the peroxide to cell, reduces malonaldehyde production quantity, therefore lycium ruthenicum is more
Sugar has certain protective effect to islet cells.
4, lycium ruthenicum is natural benefit nickel product.Chromium, nickel are also all microelements necessary to human body, but content is compared with Gao Shihui
Intoxicating phenomenon is generated, chromium has close pass with metabolism sugared in human body, the metabolism of lipid, the synthesis of protein, nucleic acid metabolism etc.
System.The content of chromium is lower than content in normal milk (5~15ug/ml) in black fruit fructus lycii, will not generate intoxicating phenomenon to human body.Nickel
In human body as bio-ligand co-factor, promote the ferric absorption of enteral, the content of nickel is than cereal butcher's meat vegetable in black fruit fructus lycii
Wanting in dish (0.1~0.3 μ g/g) is high, but the concentration range will not constitute human body to poison and threaten, therefore black fruit fructus lycii is again
With the benefit nickel agent drug effect as pure sense.Lead, cadmium are all the vertical distributions of environmental organization strict control, right
Human body is harmful and unhelpful, and the content (0.5~3.0 μ g/g) in lycium ruthenicum in the more general plant of lead, cadmium content is much lower.
5, lycium ruthenicum is natural benefit cobalt agent.Cobalt with low toxicity and participates in vitamin B12 composition and stimulates hematopoiesis to human body
It acts on, the content of cobalt in black fruit fructus lycii, much higher than 0.2~0.6ppm of content (dry weight) of green vegetable, but the concentration range is still
Human body will not be constituted to poison and threatened, black fruit fructus lycii has the function of the benefit cobalt agent drug as pure sense.
6, lycium ruthenicum has effects that anti-cancer and cancer-preventing.Lycium ruthenicum ingredient most outstanding is anthocyanidin, and anthocyanidin is good
Color pigments, even more a kind of potent antioxidant can prevent presenility, enhance blood vessel elasticity, inhibited allergy and inflammation, changed
Kind joint flexibility.Cancer is also caused by damaging inhereditary material (DNA) because of free radical.By conservation genetics substance, cyanine
Element indirectly will protect us to anticancer.Although long-term, anthocyanidin truly has indirect protective effect.And cyanine
Element removes the effect of free radical, also cancer cell can be allowed to can not be successfully diffusion, and the cell of the more health of protection is from thin by cancer whereby
Born of the same parents are corroded.On the other hand some cancers form tumour through the substance of dissolution tissue and cell, these cancer cells generate dissolution Enzyme
With albumen Enzyme, and anthocyanidin energy protected protein matter is not influenced by albumen Enzyme.
Black fruit fructus lycii is containing a certain amount of essential fatty acid and 8 kinds of amino acid needed by human, and there are also a certain amount of Vc.
Most significant is that it contains more reduced sugar and pigment, pigment be black fruit matrimony vine oxidation resistant and the activity to delay senescence at
Point, to play the role of anti-aging, there is far-reaching potentiality to be exploited.
The effect of main component seabuckthorn fruit powder:
Sea buckthorn fruit is sour-sweet, protein rich in, in more than the 20 kinds of amino acid contained by it, including 8 kinds of ammonia needed by human
Base acid.Ascorbic content is 3 times, 20 times of hawthorn, 100 times of apple of Chinese gooseberry.The content for tieing up raw yarn E is beans
30 times of oil.The content of vitamin B1 is 2 times of strawberry;Other also contain vitamin B2, citrin, folic acid, leaf amide and
Microelement and unsaturated fatty acid.Serotonin in fructus hippophae.There is significant anti-tumor activity to act on,
Often drink sea-buckthorn tea has relaxation effect to ischemic heart disease, coronary heart diseases and angina pectoris, reduces blood cholesterol triglyceride,
Myocardial blood supply state can preferably be improved;It is effective to various inflammation, it is obvious such as the effects of sphagitis, tonsillitis, prostatitis;
With bile secretion is promoted, enhance the effect of capillary function.Clinical test proves that sea-buckthorn tea can treat constipation.Due to coffee
Alkali content is low, can reduce central nervous excitation, drinks suitable for old man, hypertensive patient and its neurasthenic people.
The effect of main component avenabeta glucosan:
Beta glucan in blood glucose level, hormone response, vitamin and minerals biological effect have certain adjusting
Effect, has positive effect to preventing colon cancer.Beta glucan is low-calorie diet, not easily digested after eating, can
Slow down the increase of Glucose in Blood by Cyclic, prevention and obesity controlling disease, diabetes and cardiovascular disease.Again due to beta glucan
Have the property of water swelling, after people is edible can water swelling under one's belt, generate satiety, prevent hyperalimentation.In addition it is in intestines
It is interior to promote intestinal motility, there is osmosis in colon, prevent constipation, shorten time of the waste by enteron aisle, reduces
Pollution of the enteral carcinogenic substance to intestinal tube, reaches protective effect on cancer risk.In oral cavity, beta glucan cannot be generated the bacterium point of saprodontia
Solution produces acid and corrodes enamel, has the function of anti-caries.
Avenabeta glucosan has critically important physiology function to human health as a kind of soluble high-quality dietary fiber
Can, and largely studied and true confirmed with epidemiological survey result both at home and abroad.
Serum cholesterol is reduced, cardiovascular disease is prevented
Avenabeta glucosan can reduce human body stomach and absorb fatty mollic acid, reduce internal cholesterol biosynthesis, it was confirmed that β-Portugal is poly-
Sugar has good serum cholesterol-lowering, prevents the function of cardiovascular disease.
Blood glucose level is adjusted, diabetes are prevented
Avenabeta glucosan can improve blood flow performance, accelerate carbohydrate during being absorbed and utilized by reducing lipids contents
Transport speed and efficiency, while the hepatic and renal tissue lesion concurrent to diabetes has good repair, can effectively drop
The decomposition of low hepatic glycogen, so as to cause blood glucose reduction.
Promote proliferation of intestinal probiotics, prevents intestinal cancer
Avenabeta glucosan can promote Bifidobacterium and Bacillus acidi lactici proliferation in mouse intestinal and excrement, and inhibit large intestine bar
Bacterium breeding, improves intestinal environment, has the function of prebiotics;In addition beta glucan can also increase intestines peristalsis, and it is logical to shorten excrement
The time of large intestine is spent, increases excrement amount and defecation frequency, reduces the time of contact of noxious material and intestinal wall, reduce theirs
Toxic action.
Adjust body's immunity
Beta glucan as a kind of nonspecific immunomodulator, it can not only activate T, bone-marrow-derived lymphocyte, macrophage, from
The immunocytes such as Natural killer cell, moreover it is possible to promote cell factor to generate, activating complement system promotes antibody to generate, to siberian crabapple
System plays various adjustment effects.
The present invention is by soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder,
Avenabeta glucosan, vegetable fat powder, maltodextrin adequately combine, and mutually cooperate with, the body function of spacefarer not only can be improved,
Also there is anti-aging, the effect of beautifying face and moistering lotion.
Specific embodiment
Case study on implementation one
Soybean lecithin 25%, phosphatidylserine 17%, 4-Aminobutanoicacid 16%, Valerian root P.E 13%, 11 seabuckthorn fruit powder of black fruit fructus lycii
8%, avenabeta glucosan 6%, vegetable fat powder 3%, maltodextrin 1%
Specific production technology is as follows:
By soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, oat β-Portugal gathers
Sugar, vegetable fat powder, maltodextrin are pulverized and mixed uniformly, cross 80 meshes, and control environment temperature is lower than 30 DEG C, and humidity is lower than 50%, 60 DEG C
Drying, dresses up the pulvis of certain specification.
Case study on implementation two:
Soybean lecithin 28%, phosphatidylserine 16%, 4-Aminobutanoicacid 16%, Valerian root P.E 11%, black fruit fructus lycii 11%, sea-buckthorn
Powder 8%, avenabeta glucosan 6%, vegetable fat powder 3%, maltodextrin 1%
Specific production technology is as follows:
By soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, oat β-Portugal gathers
Sugar, vegetable fat powder, maltodextrin are pulverized and mixed uniformly, cross 80 meshes, and control environment temperature is lower than 30 DEG C, and humidity is lower than 50%, 60 DEG C
Drying, dresses up the pulvis of certain specification.
Case study on implementation three:
Soybean lecithin 24%, phosphatidylserine 18%, 4-Aminobutanoicacid 17%, Valerian root P.E 12%, black fruit fructus lycii 11%, sea-buckthorn
Powder 8%, avenabeta glucosan 6%, vegetable fat powder 3%, maltodextrin 1%
Specific production technology is as follows:
By soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, oat β-Portugal gathers
Sugar, vegetable fat powder, maltodextrin are pulverized and mixed uniformly, cross 80 meshes, and control environment temperature is lower than 30 DEG C, and humidity is lower than 50%, 60 DEG C
Drying, dresses up the pulvis of certain specification.
It is tested with said preparation:
Experiment one:
Experiment purpose: repair of this preparation to memory is studied.
Experimental method: two groups of healthy rats on inspection are looked for, two groups of rats are divided into ground group and hang tail group, two groups of rats
The multiple excessively same labyrinth before treatment records the time.Start to test later.Two groups of rats feed same food daily,
Two groups of rats cross this labyrinth respectively after one month, and the rat used time for hanging tail group is significantly more than ground group.Hung tail daily later
Group feeds this preparation, a month laggard walking maze experiment by multiple.It was found that the rat used time for hanging tail group has been restored to for the first time
Walk the time in labyrinth.
Experimental result: preparation of the invention has restitution to memory.
Experiment two:
Experiment purpose: influence of this preparation to cerebral blood flow velocity, brain resistance is studied.
Experimental method: three groups of rats are respectively ground group, hang tail group (not feeding this preparation), hang tail feed group (feed sheet
Preparation), cerebral blood flow velocity, vascular pressure and the brain drag data of three groups of rats of record before testing.Experiment 15 days, during which at any time
Monitor and record the cerebral blood flow velocity, vascular pressure and brain resistance of three groups of rats.Ground group is unchanged.Hang tail group blood flow velocity
Slow down, cerebral vascular resistance becomes larger.It hangs tail feed group initial stage blood flow velocity to slow down, cerebral vascular resistance becomes larger, and slowly restores two days later.
Experimental result: invention formulation can promote cerebral blood flow velocity, change brain resistance.
Experiment three:
Experiment purpose: influence of this preparation to bone density is studied.
Test method: 2 monthly age male Wistar rats are randomly divided into 3 groups by weight: blank group, model group, feed group.
Feed group whole process gives this preparation, begins from the 2nd week, model group and feed group are with tail-suspension simulated weightlessness 3 weeks.4th weekend
After rat is condemned to death, the B3D of its 7 different parts bones is measured respectively, wherein cranium and second dorsal vertebra Measure by buoyancy method, the
Four lumbar vertebraes, humerus, femur, radioulna and shin bone are measured with Dual-energy X-rays absorptionmetry.
Compared to the blank group, model group cranium BMD is dramatically increased (p < 0.05) test result, thoracic vertebrae, radioulna, humerus
Unchanged (p>0.05), lumbar vertebrae, femur, shin bone BMD are remarkably decreased (p<0.05, p<0.01) 1 compared with model group, feed group
Lumbar vertebrae, femur, humerus BMD are significantly improved (p < 0.05, p < 0.01), while shin bone BMD is improved trend, and cranium, radioulnar
Bone, thoracic vertebrae are unchanged (p > 0.05).
Experimental result: 3 weeks tails hang simulated weightlessness rat body BMD variation and particular tendency are presented, and head BMD is improved, upper limb
And second dorsal vertebra BMD is remained unchanged;4th abdomen vertebra and hind leg BMD decline;Invention formulation is to the weightless osteoporosis of alleviation, correction
The redistribution of weightlessness bone calcium has positive effect.
Claims (5)
1. a kind of raising spacefarer body function compound formulation, it is characterised in that: be with soybean lecithin, phosphatidylserine, 4-
Aminobutyric acid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, avenabeta glucosan, vegetable fat powder, maltodextrin are made of supplementary material
Oral powder.
2. a kind of raising spacefarer body function compound formulation according to claim 1, it is characterised in that: the component of said preparation is former
Expect that weight ratio is as follows:
Soybean lecithin 25%, phosphatidylserine 17%, 4-Aminobutanoicacid 16%, Valerian root P.E 13%, 11 seabuckthorn fruit powder of black fruit fructus lycii
8%, avenabeta glucosan 6%, vegetable fat powder 3%, maltodextrin 1%.
3. a kind of raising spacefarer body function compound formulation according to claim 1, it is characterised in that: the component of said preparation is former
Expect that weight ratio is as follows:
Soybean lecithin 28%, phosphatidylserine 16%, 4-Aminobutanoicacid 16%, Valerian root P.E 11%, black fruit fructus lycii 11%, sea-buckthorn
Powder 8%, avenabeta glucosan 6%, vegetable fat powder 3%, maltodextrin 1%.
4. a kind of raising spacefarer body function compound formulation according to claim 1, it is characterised in that: the component of said preparation is former
Expect that weight ratio is as follows:
Soybean lecithin 24%, phosphatidylserine 18%, 4-Aminobutanoicacid 17%, Valerian root P.E 12%, black fruit fructus lycii 11%, sea-buckthorn
Powder 8%, avenabeta glucosan 6%, vegetable fat powder 3%, maltodextrin 1%.
5. a kind of raising spacefarer body function compound formulation according to claim 1, it is characterised in that: concrete technology flow process:
By soybean lecithin, phosphatidylserine, 4-Aminobutanoicacid, Valerian root P.E, black fruit fructus lycii, seabuckthorn fruit powder, oat β-Portugal gathers
Sugar, vegetable fat powder, maltodextrin are pulverized and mixed uniformly, cross 80 meshes, and control environment temperature is lower than 30 DEG C, and humidity is lower than 50%, 60 DEG C
Drying, dresses up the pulvis of certain specification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910006301.8A CN110384234A (en) | 2019-01-04 | 2019-01-04 | A kind of raising spacefarer body function compound formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910006301.8A CN110384234A (en) | 2019-01-04 | 2019-01-04 | A kind of raising spacefarer body function compound formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110384234A true CN110384234A (en) | 2019-10-29 |
Family
ID=68284798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910006301.8A Withdrawn CN110384234A (en) | 2019-01-04 | 2019-01-04 | A kind of raising spacefarer body function compound formulation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110384234A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111296855A (en) * | 2020-03-18 | 2020-06-19 | 西咸新区优恩生物科技股份有限公司 | Targeting gene polypeptide nutrient for supplementing and improving physique of astronauts |
-
2019
- 2019-01-04 CN CN201910006301.8A patent/CN110384234A/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111296855A (en) * | 2020-03-18 | 2020-06-19 | 西咸新区优恩生物科技股份有限公司 | Targeting gene polypeptide nutrient for supplementing and improving physique of astronauts |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6368617B1 (en) | Dietary supplement | |
CN101574140B (en) | Drink composition with human immunity strengthening and anti-fatigue functions | |
CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
CN109645320A (en) | A kind of light jejunitas full nutrient formulation can brew instant stick and preparation method thereof | |
CN109965026A (en) | A kind of formula milk and preparation method thereof promoting child growth | |
CN106072573A (en) | A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible | |
KR101717893B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
CN109123643A (en) | A kind of preparation method of cereal generation meal ball | |
CN108077911A (en) | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof | |
CN108719984B (en) | Meal replacement nutrition bar for gout population and preparation method thereof | |
CN101507494A (en) | Special diet food for patient with hyperlipidemia and hypertension | |
CN107440120A (en) | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof | |
CN100403932C (en) | Nutrition powder for increasing memory | |
CN111296584A (en) | Formula yak milk powder for promoting height increase and brain development of children and preparation method thereof | |
CN107440121A (en) | A kind of Single Obesity tailored version clinical nutrition formula and preparation method thereof | |
CN107616490A (en) | A kind of postoperative tailored version clinical nutrition formula of children and preparation method thereof | |
CN107455625A (en) | A kind of nutrient for plants beverage and its preparation technology with antifatigue weight losing function | |
CN105232907A (en) | Beverage capable of invigorating kidney and strengthening Yang and making method thereof | |
CN109527290A (en) | A kind of preparation method of beauty collagen peptide fruity beverage | |
CN101536786A (en) | Food composition used for controlling body weight and preparation method thereof | |
CN111296585A (en) | Formula milk powder for promoting height increase and brain development of children and preparation method thereof | |
KR100561286B1 (en) | Growth-promoting Composition Comprising Dried Yeast, Extracted Natural Substances and Nutrient Mixed Powder | |
CN104856000A (en) | Non-complete-nutrition formula food for insomnia | |
CN111000230A (en) | Composition for promoting bone health and application | |
CN101791079A (en) | Capsule for reducing weight and beautifying features |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191029 |
|
WW01 | Invention patent application withdrawn after publication |